quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:55:33·129d
ANALYSTRating
Haemonetics Corporation logo

Haemonetics downgraded by Needham

HAE· Haemonetics Corporation
Health Care
Original source

Companies

  • HAE
    Haemonetics Corporation
    Health Care

Recent analyst ratings

  • Dec 15UpdateNeedham-
  • Dec 11UpdateCitigroup$88.00
  • Aug 11UpdateRaymond James$78.00
  • Aug 8UpdateAnalyst$62.00
  • Aug 8UpdateBarrington Research$86.00
  • Jul 9UpdateCitigroup$90.00

Related

  • PR47m
    New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
  • PR22d
    Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
  • PR24d
    Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Haemonetics Corporation
  • SEC51d
    Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
  • PR59d
    Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
  • PR62d
    Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
  • SEC70d
    Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022